The Valens Company Inc., a global innovator in the end-to-end development and manufacturing of innovative, cannabinoid-based products, announced that it has received an amendment to its existing Health Canada standard processing licence to allow operations to commence at its second manufacturing and processing facility in Kelowna, B.C. (“K2 Facility”). Through this licence amendment, The Valens Company significantly increases its production capacity and capabilities, further solidifying its position as one of the largest third-party manufacturers and distributors of premium cannabis derivative products in Canada.
Located beside the Company’s facility focused on cannabis processing (“K1 Facility”), the 42,000 square foot K2 Facility is equipped with the proprietary technologies and product manufacturing capabilities to significantly increase the Company’s output of finished cannabis derivative products to Canadian and international markets. The scalable K2 Facility holds the capacity to manufacture a wide range of product formats, including vapes, sprays, tinctures, capsules, topicals, in addition to small-scale beverage filling, to meet the growing demand for Cannabis 2.0 products.
Building on the expertise the Company has developed from its white label and custom manufacturing business, the K2 facility will optimize production and quality assurance efficiencies, and together with the K1 Facility, will rapidly increase its manufacturing footprint. In preparation for continued global expansion, the K2 Facility was built with Good Manufacturing Practices (GMP) compliance to support EU level certification. Additionally, The Valens Company has completed the expansion of its office space in the Kelowna, B.C. headquarters, located at the K1 and K2 site, to accommodate the Company’s growing team of employees and strengthen the resources necessary to continue to execute its corporate strategy.
“The full build-out of our K2 facility, and now the ability to commence operations, allows us to hit a key milestone in our corporate strategy by the end of fiscal 2020, which is the significant expansion of our processing and manufacturing capacity to maintain our speed to market and cost advantage across all 2.0 product categories,” said Tyler Robson, Chief Executive Officer at The Valens Company. “The investment we have made in our white label and custom manufacturing capabilities, paired with Valens’ custom-engineered processing platform, will continue to set us apart not only domestically, but in global markets as we look to replicate the success of our business model overseas. We look forward to continuing to produce the premium and reliable derivative products our customers and consumers know us for, but with this expansion, at record speeds and in new, innovative formats.”
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. For more information, please visit http://thevalenscompany.com.